对于未来的恶性肺流治疗的潜在目标:单细胞化学吸引蛋白-1 (MCP-1)
Fatih Tekin1, Deniz Koksal1,2, Z Gunnur Dikmen3
1Department of Chest Diseases, Hacettepe University Medical Faculty, Ankara, Turkey.
Cancer biomarkers : section A of Disease markers
|March 20, 2025
概括
单细胞化学吸引蛋白-1 (MCP-1) 水平在恶性流和良性排泄物中明显升高,与转化物相比. 向MCP-1可能为管理恶性多叶流血提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
背景情况:
- 恶性流 (MPE) 的管理依赖于诸如流和排水之类的侵入性手术.
- 对于MPE,需要针对液体形成分子的新疗法.
- 单细胞化学吸引蛋白-1 (MCP-1) 在MPE病变发生中的作用需要研究.
研究的目的:
- 调查MCP-1在患有转移性多性恶性瘤的患者中MPE发展中的潜在作用.
- 为了比较MCP-1水平在恶性肺溢液,良性液和透液中.
主要方法:
- 从100名被分为MPE,良性排泄物和透汗物组的患者中收集了多流液样本.
- 使用ELISA量化了多液中的MCP-1水平.
- 分析了MCP-1,乳酸脱酶 (LDH) 和多液体体积之间的相关性.
主要成果:
- 在MPE (1303 pg/ml) 和良性排泄物 (926 pg/ml) 中,MCP-1水平明显高于转排泄物 (211 pg/ml) (p < 0.001).
- 在MPE和良性排泄物组中,MCP-1水平类似.
- 在体液MCP-1和LDH水平 (r=0.38;p=0.001) 和增加体液体积 (p=0.007) 之间发现了正相关性.
结论:
- 在MPE和良性排泄物中,MCP-1水平升高表明炎症在膜溢液形成中起作用.
- MCP-1可能是流的潜在生物标志物.
- 针对MCP-1可能是MPE未来有希望的治疗策略.
相关概念视频
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Pleural Effusion II: Symptoms and Management
144
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
144
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K


